Le Lézard
Classified in: Science and technology
Subject: Event

ReposiTrak Rings NYSE Closing Bell, Marking Milestone for Company and Progress Toward Traceability


ReposiTrak (NYSE: TRAK) Chairman and CEO Randy Fields, along with the company's Board of Directors and senior leadership, rang the closing bell at the New York Stock Exchange on April 30, 2024. The event marked the company's progress toward advancing food safety and traceability in the food supply chain and its uplisting from Nasdaq to the New York Stock Exchange under its new ticker (NYSE: TRAK).

"Ringing the bell at the historic New York Stock Exchange was a milestone and one that we'll never forget," said Randy Fields, chairman and CEO of ReposiTrak. "It was a moment to acknowledge the progress we've made over the last two decades in advancing food safety and traceability across the food supply chain and also, importantly, to contemplate the road ahead."

ReposiTrak, the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, has evolved from the AMEX, to Nasdaq and in November 2023, to the NYSE. ReposiTrak serves a customer base of more than 30,000 retailers, wholesalers and suppliers in more than 110 countries through a robust solution suite consisting of three product families: food traceability, compliance and risk management, as well as supply chain solutions.

The company's newest offering, the ReposiTrak Traceability Network®, RTN, enables the exchange and maintenance of data between food supply chain operators, enabling customers to meet and exceed the requirements of the FDA's FSMA 204 food traceability law. Under FSMA 204, manufacturers, processors and those who pack or hold foods on the Food Traceability List (FTL) must establish and maintain Key Data Element (KDE) records for specific Critical Tracking Events (CTEs). As an FTL food changes hands or changes form, a compounding string of data must be transferred between trading partners to provide full, end-to-end traceability.

For the ceremony, Fields was joined by members of the ReposiTrak Board of Directors and senior leadership team, including but not limited to:

Board Members:

Leadership:

Watch a video of the day's events: https://repositrak.com/blog/this-week-at-the-new-york-stock-exchange-a-milestone-for-repositrak-in-advancing-food-safety-and-traceability/

About ReposiTrak

ReposiTrak (NYSE: TRAK), formerly Park City Group, provides retailers, suppliers and wholesalers with a robust solution suite consisting of three product families: food traceability, compliance and risk management and supply chain solutions. ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit https://repositrak.com/.


These press releases may also interest you

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: